{"id":"actinium-ac-225-dota-daratumumab","safety":{"commonSideEffects":[{"rate":"30%","effect":"Nausea"},{"rate":"20%","effect":"Vomiting"},{"rate":"15%","effect":"Diarrhea"},{"rate":"10%","effect":"Fatigue"},{"rate":"5%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL4297554","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Actinium Ac 225-DOTA-Daratumumab is a radioligand therapy that targets CD38, a transmembrane glycoprotein involved in the immune response. By binding to CD38, the drug delivers alpha-particle radiation to cancer cells, leading to cell death.","oneSentence":"Targeting CD38 with a radioligand","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:32:48.613Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05363111","phase":"PHASE1","title":"Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-11-22","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":15},{"nctId":"NCT06287944","phase":"PHASE1","title":"225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-07-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["225Ac-DOTA-Daratumumab; [225Ac]-DOTA-Daratumumab","225Ac-DOTA-Daratumumab","[225Ac]-DOTA-Daratumumab"],"phase":"phase_1","status":"active","brandName":"Actinium Ac 225-DOTA-Daratumumab","genericName":"Actinium Ac 225-DOTA-Daratumumab","companyName":"City of Hope Medical Center","companyId":"city-of-hope-medical-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"Targeting CD38 with a radioligand Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}